<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">I.P. Pavlov Journal of Higher Nervous Activity</journal-id><journal-title-group><journal-title xml:lang="en">I.P. Pavlov Journal of Higher Nervous Activity</journal-title><trans-title-group xml:lang="ru"><trans-title>Журнал высшей нервной деятельности им. И.П. Павлова</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0044-4677</issn><issn publication-format="electronic">3034-5316</issn><publisher><publisher-name xml:lang="en">The Russian Academy of Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">692571</article-id><article-id pub-id-type="doi">10.31857/S0044467725050011</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ФИЗИОЛОГИЧЕСКИЕ МЕХАНИЗМЫ ПОВЕДЕНИЯ ЖИВОТНЫХ: &#13;
ВОСПРИЯТИЕ ВНЕШНИХ СТИМУЛОВ, ДВИГАТЕЛЬНАЯ &#13;
АКТИВНОСТЬ, ОБУЧЕНИЕ И ПАМЯТЬ</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ФИЗИОЛОГИЧЕСКИЕ МЕХАНИЗМЫ ПОВЕДЕНИЯ ЖИВОТНЫХ: ВОСПРИЯТИЕ ВНЕШНИХ СТИМУЛОВ, ДВИГАТЕЛЬНАЯ АКТИВНОСТЬ, ОБУЧЕНИЕ И ПАМЯТЬ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Behavior of mice differing by relative brain weight. High doses of memantine influence</article-title><trans-title-group xml:lang="ru"><trans-title>Влияние высоких доз мемантина на поведение мышей, различающихся по относительному весу мозга</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ogienko</surname><given-names>N. A.</given-names></name><name xml:lang="ru"><surname>Огиенко</surname><given-names>Н. А.</given-names></name></name-alternatives><email>ingapoletaeva@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Revishchin</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Ревищин</surname><given-names>А. В.</given-names></name></name-alternatives><email>ingapoletaeva@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Pavlova</surname><given-names>G. V.</given-names></name><name xml:lang="ru"><surname>Павлова</surname><given-names>Г. В.</given-names></name></name-alternatives><email>ingapoletaeva@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Perepelkina</surname><given-names>O. V.</given-names></name><name xml:lang="ru"><surname>Перепелкина</surname><given-names>О. В.</given-names></name></name-alternatives><email>ingapoletaeva@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Poletaeva</surname><given-names>I. I.</given-names></name><name xml:lang="ru"><surname>Полетаева</surname><given-names>И. И.</given-names></name></name-alternatives><email>ingapoletaeva@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Department of Higher Nervous Activity, Biological Faculty, Lomonosov Moscow State University</institution></aff><aff><institution xml:lang="ru">Кафедра высшей нервной деятельности, Биологический факультет МГУ им. М. В. Ломоносова</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Institute of Higher Nervous Activity and Neurophysiology, RAS</institution></aff><aff><institution xml:lang="ru">Институт высшей нервной деятельности и нейрофизиологии РАН</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2025-10-15" publication-format="electronic"><day>15</day><month>10</month><year>2025</year></pub-date><volume>75</volume><issue>5</issue><issue-title xml:lang="en">VOL 75, NO5 (2025)</issue-title><issue-title xml:lang="ru">ТОМ 75, №5 (2025)</issue-title><fpage>636</fpage><lpage>646</lpage><history><date date-type="received" iso-8601-date="2025-10-08"><day>08</day><month>10</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Russian Academy of Sciences</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Российская академия наук</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Russian Academy of Sciences</copyright-holder><copyright-holder xml:lang="ru">Российская академия наук</copyright-holder></permissions><self-uri xlink:href="https://innoscience.ru/0044-4677/article/view/692571">https://innoscience.ru/0044-4677/article/view/692571</self-uri><abstract xml:lang="en"><p>Mice of two strains, differing by the relative brain weight (LB and SB) displayed differential behavioral effects after 7-day exposure to 50 mg/kg of memantine injections, the non-competitive NMDA-rec antagonist. Memantine increased the exploration behavior in LB mice as well as their reaction to novelty, while SB mice demonstrated the activation of behavior after the control saline injections. The number of newly developed neuronal elements in the hippocampal subgranular zone of dentate gyrus in LB (but not SB) mice subjected to memantine was higher in comparison to controls. In the intact samples of mouse strains used in this work no significant behavioral differences were found, which accentuated the genotype-dependent effects of memantine injections.</p></abstract><trans-abstract xml:lang="ru"><p>На мышах двух линий, различающихся по относительному весу мозга (большой мозг и малый мозг, далее БМ и ММ), продемонстрированы сложные эффекты семидневного внутрибрюшинного введения мемантина (антагониста NMDA-рецепторов, доза 50 мг/кг). Мемантин усилил исследовательское поведение у мышей линии БМ (но не ММ) и их реакцию на новизну. У мышей ММ контрольной группы после введения физиологического раствора выполнение теста было более успешным, чем у такой же группы мышей БМ. Мемантин дифференциально влиял на успешность выполнения когнитивного теста на “неисчезаемость” у мышей БМ и ММ – поддерживал выполнение теста у мышей ММ на стабильно устойчивом уровне, тогда как у мышей БМ наблюдалось резкое снижение успешности выполнения наиболее “трудных” предъявлений теста. В субгранулярной зоне зубчатой извилины гиппокампа после введения мемантина у мышей БМ (но не ММ) было значимо больше новых нейральных клеточных элементов по сравнению с контролем. В использованной выборке интактных мышей БМ и ММ в исследованном поколении статистически значимых межлинейных различий в выполнении когнитивного теста обнаружено не было. Поскольку введение мемантина их выявило, это может быть свидетельством генотип-зависимых различий в поведении мышей БМ и ММ.</p></trans-abstract><kwd-group xml:lang="en"><kwd>animal behavior</kwd><kwd>novelty reaction</kwd><kwd>exploration</kwd><kwd>memantine</kwd><kwd>mouse strains</kwd><kwd>adult neurogenesis</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>поведение животных</kwd><kwd>реакция на новизну</kwd><kwd>исследовательское поведение</kwd><kwd>мемантин</kwd><kwd>вес мозга</kwd><kwd>нейрогенез взрослого мозга</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена при финансовой поддержке Российского фонда фундаментальных исследований (№ 20-015-00287a) и Российского научного фонда (№ 23-25-00042), а также в рамках тем госрегистрации № 121032500080-8, научного проекта государственного задания МГУ "Нейробиологические основы поведения животных" и № 1021062411632-1-3.1.4, госзадания Министерства образования и науки Российской Федерации "Нейрогенетическая и эпигенетическая обусловленность нормы и патологии головного мозга животных".</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Перепелкина О.В., Тарасова А.Ю., Огиенко Н.А., Лильп И.Г., Полетаева И.И. Вес мозга и когнитивные способности лабораторной мыши. Усп. совр. биол. 2019. 139 (5): 434–445.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Перепелкина О.В., Полетаева И.И., Поварнина П.Ю., Гудашева Т.А. Влияние низкомолекулярного миметика NGF дипептида ГК-2 на поведение мышей аутбредных линий, различающихся по весу мозга. Усп. совр. биол., 2024. 144 (4): 461–471.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Chen Y-C., Holmes A. Effects of topiramate and other anti-glutamatergic drugs on the acute intoxicating actions of ethanol in mice: modulation by genetic strain and stress. Neuropsychopharm. 2009. 34 (6): 1454–1466. https://doi.org/10.1038/npp.2008.182</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Egunlusi A.O., Joubert J. NMDA Receptor Antagonists: Emerging Insights into Molecular Mechanisms and Clinical Applications in Neurological Disorders. Pharmaceuticals. 2024. 17 (5): 639. https://doi.org/10.3390/ph17050639</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Galsworthy M.J., Jose L. Paya-Cano J.L., Lin Liu L., Monleón S., Gregoryan G. et al. Cognitive Ability in a Battery of Cognitive Tasks for Laboratory Mice. Behavior Genetics, 2005. 35: 675–692.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Ishikawa R., Kim R., Namba T., Kohsaka S., Uchino S., Kida S. Time-dependent enhancement of hippocampus-dependent memory after treatment with memantine: implications for enhanced hippocampal adult neurogenesis. Hippocampus. 2014. 24: 784–793.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Kuns B., Rosani A., Patel P., Varghese D. Memantine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2025.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Lau A., Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflügers Archiv: Eur. J. Physiol. 2010, 460: 525–542. https://doi.org/10.1007/s00424-010-0809-1</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Lipton S.A.J. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer’s disease and other neurologic disorders. Alzheimers Dis. 2004. 6 (6 Suppl): S61–74. https://doi.org/10.3233/jad-2004-6s610</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Marvanová M., Lakso M., Pirhonen J., Nawa H., Wong G., Castrén E. The neuroprotective agent memantine induces brain-derived neurotrophic factor and trkB receptor expression in rat brain. Mol. Cell Neurosci. 2001. 18 (3): 247–258.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Мaeda S., Yamada J., Iinuma K.M., Nadanaka S., Kitagawa H., Jinno S. Chondroitin sulfate proteoglycan is a potential target of memantine to improve cognitive function via the promotion of adult neurogenesis. Br.J. Pharmacol. 2022. 179 (20): 4857–4877. https://doi.org/10.1111/bph.15920</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Maekawa M., Namba T., Suzuki E., Yuasa S., Kohsaka S., Uchino S. NMDA receptor antagonist memantine promotes cell proliferation and production of mature granule neurons in the adult hippocampus. Neurosci Res. 2009. 63 (4): 259–266.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Matsumura M., Sato K., Kubota T., Kishimoto Y. Spatial and latent memory data in PS2Tg2576 Alzheimer’s disease mouse model after memantine treatment. Data Brief. 2021. 12. 36: 107131. https://doi.org/10.1016/j.dib.2021.107131</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Minkeviciene R., Banerjee P., Tanila H. Cognition-enhancing and anxiolytic effects of memantine. Neuropharmacology. 2008. 54 (7): 1079–1085. https://doi.org/10.1016/j.neuropharm.2008.02.014</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>More L., Gravius A., Nagel J., Valastro B., Greco S., Danysz W. Therapeutically relevant plasma concentrations of memantine produce significant NMDA receptor occupancy and do not impair learning in rats. Behav. Pharmacol. 2008. 19: 724–734.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Neale J.H., Olszewski R. A role for N-acetylaspartylglutamate (NAAG) and mGluR3 in cognition. Neurobiol Learn Mem. 2019. 158: 9–13. https://doi.org/10.1016/j.nlm.2019.01.006</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Onogi H., Ishigaki S., Nakagawasai O., Arai-KatoY., Arai Y., Watanabe H. et al. Influence of memantine on brain monoaminergic neurotransmission parameters in mice: neurochemical and behavioral study. Biol Pharm Bull. 2009. 32 (5): 850–855. https://doi.org/10.1248/bpb.32.850</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Parsons C.G., Stoffler A., Danysz W. Memantine: a NMDA receptor worse antagonist that improves memory by restoration of homeostasis in the glutamatergic system – too little activation is bad, too much is even worse. Neuropharmacology. 2007. 53: 699e723.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Pepeu G., Blandina P.J. The acetylcholine, GABA, glutamate triangle in the rat forebrain. Physiol Paris. 1998. 92 (5–6): 351–355. https://doi.org/10.1016/S0928-4257(99)80004-7</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Perepelkina O.V., Poletaeva I.I. Cognitive test solution in mice with different brainweights after atomoxetine. Neurol.Intern. 2023. 15 (2): 649–660.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Petrović M., Horák M., Sedlácek M., Vyklický L. Jr. Physiology and pathology of NMDA receptors. Prague Med Rep. 2005. 106 (2): 113–136.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Réus G.Z., Valvassori S.S., Machado R.A., Martins M.R., Gavioli E.C., Quevedo J. Acute treatment with low doses of memantine does not impair aversive, non-associative and recognition memory in rats. Naunyn Schmiedebergs Arch Pharmacol. 2008. 376 (5): 295–300. https://doi.org/10.1007/s00210-007-0235-x</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Saeedi M., Mehranfar F. Challenges and approaches of drugs such as memantine, donepezil, rivastigmine, and aducanumab in the treatment, control and management of Alzheimer’s disease. Recent Pat. Biotechnol. 2022. 16 (2): 102–121. https://doi.org/10.2174/1872208316666220302115901</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Stazi M., Wirths O. Chronic memantine treatment ameliorates behavioral deficits, neuron loss, and impaired neurogenesis in a model of Alzheimer’s disease. Mol. Neurobiol. 2021. 58 (1): 204–216. https://doi.org/10.1007/s12035-020-02120-z</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Tari P.K., Parsons C.G., Collingridge G.L., Rammes G. Memantine: Updating a rare success story in pro-cognitive therapeutics. Neuropharmacol. 2024. 244: 109737. https://doi.org/10.1016/j.neuropharm.2023.109737</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Wesierska M.J., Duda W., Dockery C.A. Low-dose memantine-induced working memory improvement in the allothetic place avoidance alternation task (APAAT) in young adult male rats. Front. Behav. Neurosci. 2013. 7: 203.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Wise L.E., Lichtman A.H. The uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist memantine prolongs spatial memory in a rat delayed radial-arm maze memory task. Eur. J. Pharmacol. 2007. 575: 98–102.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Wu H.M., Tzeng N.S., Qian L., Wei S.J., Hu X., Chen S.H. et al. Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation. Neuropsychopharm. 2009. 34 (10): 2344–2357.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Yu S.P., Jiang M.Q., Shim S.S., Pourkhodadad S., Wei L. Extrasynaptic NMDA receptors in acute and chronic excitotoxicity: implications for preventive treatments of ischemic stroke and late-onset Alzheimer’s disease. Mol. Neurodegener. 2023. 18 (1): 43. https://doi.org/10.1186/s13024-023-00636-1</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Zheng X., Li W., Xiang Q., Wang Y., Qu T., Fang W., Yang H. Memantine attenuates cognitive and emotional dysfunction in mice with sepsis-associated encephalopathy. ACS Omega. 2023. 8 (43): 40934–40943. https://doi.org/10.1021/acsomega.3c06250</mixed-citation></ref></ref-list></back></article>
